In a speech on Nov 12, 2014 at the 10th annual Personalized Medicine Conference, FDA head Dr. Margaret Hamburg provided some data to help give perspective on how much progress has been made in advancing personalized medicine.
There have been some interesting developments over the last few weeks in the ongoing discussion about FDA's desire to regulate LDTs.
We have been going through the exercise of trying to figure out how many research professionals there are in drug and diagnostics companies whose job it is to track and utilize information about biomarkers. In so doing we discovered a significant and interesting correlation.
In a previous post I questioned whether ovarian cancer is being under-served by personalized medicine, and promised to dig a bit deeper into some of the advancements that ARE being made for this disease.